Zoetis Inc. (ZTS): 10-K filed February 13, 2025

AI analysis of the 10-K that Zoetis Inc. filed with the U.S. SEC on February 13, 2025, grounded in the primary-source EDGAR filing.

• Stable Risk Profile: No material new negative events identified; risk landscape remains consistent with prior year and typical for pharmaceutical/animal health sectors (patent expiration, generic competition, regulatory pressure)

• International Exposure Remains Key Consideration: Significant geographic diversification creates persistent FX and geopolitical risks, though no acute new threats emerged during the period

• Moderately Optimistic Outlook: Management tone reflects cautious optimism (0.55 sentiment score), suggesting confidence in operations while acknowledging inherent industry headwinds and uncertainties

• No Risk Escalation Detected: Standard industry pressures present but filing language indicates no material acceleration in competitive, regulatory, or product liability threats

Filing analysis — key questions

Answers are generated from this SEC filing and StockHuntr's analysis. Not investment advice.

What does Zoetis Inc. (ZTS)'s 10-K filed February 13, 2025 say?

Company Overview: Zoetis Inc. is a pharmaceutical company (SIC 2834) headquartered in Parsippany, New Jersey, specializing in animal health products and services with fiscal year ending December 31, 2024 Financial Reporting Structure: The filing contains comprehensive financial statements, XBRL-formatted data, and detailed disclosures covering the full fiscal year 2024, with comparative data for…

Is ZTS's 10-K bullish or bearish?

Our analysis rates this filing NEUTRAL. Zoetis presents an ELEVATED but stable risk profile typical of a mature pharmaceutical company in the animal health sector. The concern level of 5.8/10 reflects a balanced picture: while the company faces two high-severity risks (regulatory pricing pressure…

How concerning is ZTS's latest 10-K?

Concern level: ELEVATED (5.8/10). Key factors: Two high-severity risks identified (severity 7/10): Regulatory/reimbursement pressure and biosimilar/generic competition intensification; Four additional material risks at severity 6/10: geopolitical/trade policy exposure, FX volatility, M&A execution risk, animal disease outbreak risk, and product liability; Significant international revenue…

What are the main risks flagged in ZTS's 10-K?

Notable risk changes: No material new negative events detected in 10-K filing - risk profile appears stable year-over-year with standard pharmaceutical/animal health industry risks; Company maintains significant international exposure (multiple countries disclosed in geographic segments) creating ongoing FX and geopolitical risk, but no new acute threats identified; Standard pharmaceutical industry risks (patent…

About this analysis

Primary source:
View this 10-K on SEC EDGAR
Additional data:
Yahoo Finance (market data)
Method:
StockHuntr analyzes filings with AI — see our methodology.
Analysis as of:
February 13, 2025
Published by:
StockHuntr

For research and education only. Nothing here is investment advice.

📄

Fetching Filing from SEC

Downloading filing HTML from SEC.gov...

15% Complete
1
Fetch filing from SEC
2
Parse document sections
3
Fetch prior filing
4
Analyze risk factors
5
Analyze management sentiment
6
Extract financial metrics
7
Compare to analyst consensus
8
Run ML prediction model
9
Finalize analysis

Note: Analysis typically takes 30-60 seconds. We're fetching real SEC filing data and running AI analysis on the actual content.